Slide 1: Orion Financial Review for 2015
Orion Financial Review for 2015 2 February 2016 Timo Lappalainen President & CEO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of these strat
Slide 3: Solid year in challenging environment
Solid year in challenging environment • Net sales and operating profit at similar level to comparative period • Product sales grew well and margin level improved • Specialty Products growing strongly • In Europe extension of generic competition to Stalevo outside Germany had no material impact yet •
Slide 4: Net sales and operating profit
Net sales and operating profit Cash flow per share Net sales, Operating profit, Basic earnings per Laimentamaton Osakekohtainen rahavirta osakekohtainen tulos, € before financial ennen items, rahoituseriä, € EUR million EUR million share, EUR EUR 272 267 1.72 1015 1015 1016 1016 1.50 1.48 1.51 2014
Slide 5: Breakdown of net sales
Breakdown of net sales Group’s net sales in 2015 were EUR 1,016 million By business division By market area 6% 4% 5% 14% 32% 31% 7% 8% 46% 31% 16% Proprietary Products Specialty Products Animal Health Finland Scandinavia Fermion Other Europe North America Contract manufacturing & other Orion Diagnos
Slide 6: Business Reviews
Business Reviews
Slide 7: Pharmaceuticals business
Pharmaceuticals business 2014 2015 Net sales split EUR million 2015 2014 Change % 962 961 Proprietary Products 323 373 -14% Specialty Products 471 427 +10% Animal Health 77 70 +10% Fermion 53 57 -8% 276 269 Contract manufacturing & other 37 34 +9% • Net sales excluding branded Parkinson’s drugs, Net
Slide 8: Best-selling pharmaceuticals 2015
Best-selling pharmaceuticals 2015 Net sales 2015 Change Product Indication EUR million vs. 2014 Parkinson’s disease 138 -19% Asthma, COPD 51 +45% Acute decompensated heart 51 +9% failure Intensive care sedative 45 +26% Rheumatoid arthritis, 28 +404% inflammatory bowel diseases Animal sedatives 27 +1
Slide 9: Orion clear market leader in Finland
Orion clear market leader in Finland Finnish human pharmaceuticals Finland’s biggest pharmaceutical market in 2015 companies in 2015 EUR million Wholesale, EUR million 300 270 2 167 250 Orion’s market +3% 200 share 12% 2 239 150 131 133 Orion in Finnish human 110 121 pharmaceuticals market, EUR 100
Slide 10: Specialty Products growing strongly in Scandinavia
Specialty Products growing strongly in Scandinavia Net sales in different market Net sales 2015 Muutos areas in 2015 (EUR million) TOP 3 Products EUR million vs. 2014 28 +404% Vs. Scandinavia 2014 Generic entacapone products 25 -2% 75 +49% Vs. Finland 2014 23 -2% 276 +8% • Depreciation of rouble wea
Slide 11: Parkinson's drugs
Parkinson’s drugs 60 Market shares of Orion’s MAT9/ MAT9/ branded Parkinson’s drugs 2015 2014 50 Finland 1) 15% 21% 40 Sweden 1) 11% 14% EUR million 30 Norway 1) 15% 15% Denmark 1) 8% 14% 20 Germany 2) 10% 14% 10 UK 2) 12% 12% 0 United States 2) 3) 2% 2% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2013 2014
Slide 12: Easyhaler product family and Simdax
Easyhaler® product family and Simdax® Simdax 16 16 14 14 12 12 EUR million EUR million 10 10 8 8 6 6 4 4 2 2 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2013 2014 2015 2013 2014 2015 Others Bufomix Easyhaler Simdax 12 2 February 2016 Orion Financial Review for 2015
Slide 13: Dexdor intensive care sedative
dexdor® intensive care sedative European sedative market MAT9/2015* Dexdor sales Total market value EUR 519 million (+4%) 14 12% 12 7% 10 EUR million 15% 8 66% 6 4 Propofol EUR 343 million (+2%) 2 Midazolam EUR 76 million (-0%) 0 Dexmedetomidine EUR 34 million (+32%) Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4 Remifen
Slide 14: Key clinical pharmaceutical development projects 1/2
Key clinical pharmaceutical development projects 1/2 Project Indication PHASE Registration Easyhaler® budesonide-formoterol 1) Asthma, COPD I II III Registration Easyhaler® salmeterol-fluticasone Asthma, COPD I II III Prostate cancer ODM-201 (androgen receptor inhibitor) 2) (nm-CRPC) I II III Low Ca
Slide 15: Key clinical pharmaceutical development projects 2/2
Key clinical pharmaceutical development projects 2/2 Project Indication PHASE Registration ODM-104 (more effective COMT inhibitor) Parkinson’s disease I ODM-203 (targeted FGFR+VEGFR inhibitor) Solid tumours I ODM-204 (CYP17 enzyme and androgen receptor inhibitor) Prostate cancer I ODM-108 (negative
Slide 16: Diagnostics business
Diagnostics business 2014 2015 • Operating profit growth mainly due to favourable margin 56 58 structure of sales from portfolio and exchange rate changes • QuikRead® tests remained the 6.4 8.5 main product • Launching of the first Orion Net sales, Operating profit, GenRead® test system products EUR
Slide 17: Outlook for 2016
Outlook for 2016 Net sales are estimated to be at similar level to 2015 Net sales (net sales were EUR 1,016 million in 2015). Operating profit Operating profit is estimated to exceed EUR 240 million. 17 2 February 2016 Orion Financial Review for 2015
Slide 18: Orion Calendar 2016
Orion Calendar 2016 Annual General Meeting 2016 Tue 22 Mar 2016 Interim Report January─March 2016 Wed 27 Apr 2016 Half-Yearly Report January─June 2016 Tue 19 Jul 2016 Interim Report January─September 2016 Tue 25 Oct 2016 The Financial Statements, Report by the Board of Directors and Corporate Govern
Slide 19: Orion - Building well-being
GRION Building well-being